US2022218696A1PendingUtilityA1

Medication for covid-19

52
Assignee: MARV ENTPR LLCPriority: Jan 10, 2021Filed: Jan 10, 2022Published: Jul 14, 2022
Est. expiryJan 10, 2041(~14.4 yrs left)· nominal 20-yr term from priority
Inventors:Mitchell S. Felder
A61K 31/315A61K 31/4045A61K 31/485A61K 31/593
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An embodiment provides a compound for treatment of Covid-19 in a patient, including: a dose comprising: an amount of naltrexone; an amount of vitamin D; an amount of melatonin; and an amount of zinc picolinate in a dose. Other aspects are described and claimed.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound for treatment of Covid-19 in a patient, comprising:
 a dose comprising:   an amount of naltrexone;   an amount of vitamin D;   an amount of melatonin; and   an amount of zinc picolinate in a dose.   
     
     
         2 . The compound of  claim 1 , wherein the amount of naltrexone is between 1-10 milligrams. 
     
     
         3 . The compound of  claim 1 , wherein the amount of naltrexone is between 2-5 milligrams. 
     
     
         4 . The compound of  claim 1 , wherein the amount of vitamin D is between 2,000 to 20,000 IU. 
     
     
         5 . The compound of  claim 1 , wherein the amount of vitamin D is between 8,000 to 12,000 IU. 
     
     
         6 . The compound of  claim 1 , wherein the amount of melatonin is between 5 and 30 milligrams. 
     
     
         7 . The compound of  claim 1 , wherein the amount of melatonin is between 8 and 12 milligrams. 
     
     
         8 . The compound of  claim 1 , wherein the amount of zinc picolinate is between 11 and 55 milligrams. 
     
     
         9 . The compound of  claim 1 , wherein the amount of zinc picolinate is between 20 and 25 milligrams. 
     
     
         10 . The compound of  claim 1 , wherein the compound is a pill administered orally. 
     
     
         11 . A method for treatment of Covid-19 in a patient, comprising:
 preparing an amount of naltrexone, an amount of vitamin D, an amount of melatonin, and an amount of zinc picolinate in a dose;   administering the dose to the Covid-19 patient.   
     
     
         12 . The method of  claim 11 , wherein the amount of naltrexone is between 1-10 milligrams. 
     
     
         13 . The method of  claim 11 , wherein the amount of naltrexone is between 2-5 milligrams. 
     
     
         14 . The method of  claim 11 , wherein the amount of vitamin D is between 2,000 to 20,000 IU. 
     
     
         15 . The method of  claim 11 , wherein the amount of vitamin D is between 8,000 to 12,000 IU. 
     
     
         16 . The method of  claim 11 , wherein the amount of melatonin is between 5 and 30 milligrams. 
     
     
         17 . The method of  claim 11 , wherein the amount of melatonin is between 8 and 12 milligrams. 
     
     
         18 . The method of  claim 11 , wherein the amount of zinc picolinate is between 11 and 55 milligrams. 
     
     
         19 . The compound of  claim 11 , wherein the amount of zinc picolinate is between 20 and 25 milligrams. 
     
     
         20 . A method for treatment of Covid-19 in a patient, comprising:
 preparing a compound using one or more of an amount of naltrexone, an amount of vitamin D, an amount of melatonin, and an amount of zinc picolinate in a dose; and   administering the dose to the Covid-19 patient.

Join the waitlist — get patent alerts

Track US2022218696A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.